Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Linking the generation of DNA adducts to lung cancer.
Ceppi M, Munnia A, Cellai F, Bruzzone M, Peluso MEM. Ceppi M, et al. Among authors: bruzzone m. Toxicology. 2017 Sep 1;390:160-166. doi: 10.1016/j.tox.2017.09.011. Epub 2017 Sep 18. Toxicology. 2017. PMID: 28928033 Review.
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Martel S, Bruzzone M, Ceppi M, Maurer C, Ponde NF, Ferreira AR, Viglietti G, Del Mastro L, Prady C, de Azambuja E, Lambertini M. Martel S, et al. Among authors: bruzzone m. Cancer Treat Rev. 2018 Jan;62:123-132. doi: 10.1016/j.ctrv.2017.09.009. Epub 2017 Nov 3. Cancer Treat Rev. 2018. PMID: 29108713 Review.
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
Poggio F, Bruzzone M, Ceppi M, Conte B, Martel S, Maurer C, Tagliamento M, Viglietti G, Del Mastro L, de Azambuja E, Lambertini M. Poggio F, et al. Among authors: bruzzone m. ESMO Open. 2018 Jun 20;3(4):e000361. doi: 10.1136/esmoopen-2018-000361. eCollection 2018. ESMO Open. 2018. PMID: 29942664 Free PMC article.
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Caparica R, Bruzzone M, Poggio F, Ceppi M, de Azambuja E, Lambertini M. Caparica R, et al. Among authors: bruzzone m. Breast Cancer Res Treat. 2019 Feb;174(1):27-37. doi: 10.1007/s10549-018-5055-9. Epub 2018 Nov 21. Breast Cancer Res Treat. 2019. PMID: 30465156
446 results